Blog Band - Page 14 of 299

09

Sep 2025

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis

Shots: The P-III (ASCEND) trial evaluated rocatinlimab (150 or 300mg, Q4W/Q8W) in ~2,600 atopic dermatitis pts who completed 24wks. in ROCKET trial program & continued for 32wks. in ASCEND, which…

09

Sep 2025

NEWS

Novartis to Acquire Tourmaline Bio for ~$1.4B, Complementing its Cardiovascular Portfolio

Shots: Novartis has entered into an agreement to acquire Tourmaline Bio, incl. its asset pacibekitug, expanding its cardiovascular portfolio As per the deal, Novartis, through its subsidiary, will acquire Tourmaline for…

08

Sep 2025

SPOTLIGHT

CXO Talks: Rick Modi from Affinia Therapeutics in a Stirring Dialogue Exchange with PharmaShots

Shots: In this episode of the CXO Talks podcast, PharmaShots speaks with Rick Modi, CEO at Affinia Therapeutics Driven by cutting-edge innovation, Affinia is pioneering and re-imagining adeno-associated virus serotype…

08

Sep 2025

VIEWPOINTS

Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots

Shots: The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes…

08

Sep 2025

NEWS

Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Shots: Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD) vs chemoimmunotherapy (bendamustine + rituximab) in 282 pts with 1L chronic lymphocytic leukemia or small…

08

Sep 2025

VIDEO

LIFE SCIENCES | DAILY NEWS | SEP 08, 2025 | PHARMASHOTS

08

Sep 2025

NEWS

ONWARD Medical’s ARC-EX System Receives the European CE Mark Approval for Spinal Cord Stimulation

Shots: ONWARD Medical has received MDR CE Mark approval for its ARC-EX system to treat people with spinal cord injury (SCI); first EU commercial sales are expected by Q4’25 Approval…

08

Sep 2025

NEWS

Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M

Shots: Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS) As per the deal, Kaerus will receive a…

08

Sep 2025

NEWS

AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC

Shots: AstraZeneca has reported P-III (FLAURA2) trial findings on Tagrisso + Pt-based CT as a 1L treatment of pts with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC…

08

Sep 2025

NEWS

Hengrui Pharma Enters a ~$1.08B Deal with Braveheart Bio for HRS-1893

Shots: Hengrui Pharma & Braveheart Bio have entered into an exclusive license agreement for Hengrui’s HRS-1893 to treat cardiovascular diseases As per the deal, Braveheart will obtain exclusive global rights…

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis

Novartis to Acquire Tourmaline Bio for ~$1.4B, Complementing its Cardiovascular Portfolio

CXO Talks: Rick Modi from Affinia Therapeutics in a Stirring Dialogue Exchange with PharmaShots

Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots

Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for 1L Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

LIFE SCIENCES | DAILY NEWS | SEP 08, 2025 | PHARMASHOTS

ONWARD Medical’s ARC-EX System Receives the European CE Mark Approval for Spinal Cord Stimulation

Servier to Acquire KER-0193 from Kaerus Bioscience for ~$450M

AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC

Hengrui Pharma Enters a ~$1.08B Deal with Braveheart Bio for HRS-1893

Contact US

OUR INFORMATION

FOLLOW US